A phase II trial of SU5416 [semaxanib] (NSC686819) in patients with hormone-refractory prostate cancer
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Semaxanib (Primary) ; Dexamethasone
- Indications Prostate cancer
- Focus Therapeutic Use
- 05 Sep 2013 Biomarkers information updated
- 07 Feb 2013 Primary endpoint added as reported by ClinicalTrials.gov record.
- 07 Feb 2013 Actual end date added as 1 Jan 2006 as reported by ClinicalTrials.gov record.